Merian Life Sciences ApS Financials, key figures and credit report
Gross profit 280.8 kDKK FY 2025 -73.8% vs 2024
EBIT 280.8 kDKK FY 2025 -73.8% vs 2024
Net debt -2 124.8 kDKK FY 2025 -39.8% vs 2024
Quick ratio 5.7 FY 2025 +1.1 vs 2024
Income statement (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | 424.24 | 595.59 | 469.18 | 1 072.06 | 280.80 |
| Employee benefit expenses | -4.06 | -1.92 | |||
| EBIT | 420.18 | 593.66 | 469.18 | 1 072.06 | 280.80 |
| Other financial income | 0.83 | 11.01 | 15.04 | 18.79 | 13.12 |
| Other financial expenses | -12.07 | -15.96 | -4.28 | -4.94 | -23.73 |
| Reduction non-current investment assets | -29.80 | -25.20 | -51.00 | -9.00 | - 304.00 |
| Pre-tax profit | 379.14 | 563.51 | 428.94 | 1 076.92 | -33.81 |
| Income taxes | -88.86 | - 130.46 | -98.82 | - 241.43 | -3.10 |
| Net earnings | 290.28 | 433.05 | 330.11 | 835.49 | -36.91 |
Assets (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Intangible assets total | |||||
| Tangible assets total | |||||
| Investments total | |||||
| Non-curr. owed by group member comp. | 568.10 | 532.14 | 541.94 | 244.02 | |
| Long term receivables total | 568.10 | 532.14 | 541.94 | 244.02 | |
| Inventories total | |||||
| Current trade debtors | 200.00 | 525.00 | |||
| Current other receivables | 2.51 | 11.14 | 42.62 | 43.73 | 6.93 |
| Short term receivables total | 2.51 | 211.14 | 42.62 | 568.73 | 6.93 |
| Cash and bank deposits | 1 056.07 | 622.99 | 1 204.06 | 1 520.39 | 2 124.78 |
| Cash and cash equivalents | 1 056.07 | 622.99 | 1 204.06 | 1 520.39 | 2 124.78 |
| Balance sheet total (assets) | 1 058.58 | 1 402.23 | 1 778.83 | 2 631.05 | 2 375.73 |
Equity and liabilities (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Share capital | 50.00 | 50.00 | 50.00 | 50.00 | 50.00 |
| Shares repurchased | 114.40 | 117.80 | 122.00 | 135.00 | 158.80 |
| Retained earnings | 475.69 | 648.17 | 959.22 | 1 154.33 | 1 831.02 |
| Profit of the financial year | 290.28 | 433.05 | 330.11 | 835.49 | -36.91 |
| Shareholders equity total | 930.37 | 1 249.02 | 1 461.33 | 2 174.82 | 2 002.91 |
| Non-current liabilities total | |||||
| Current trade creditors | 16.00 | 19.00 | 199.49 | 205.58 | 148.86 |
| Short-term deferred tax liabilities | 56.86 | 90.46 | 58.82 | 189.43 | 140.53 |
| Other non-interest bearing current liabilities | 55.36 | 43.76 | 59.18 | 61.22 | 83.43 |
| Current liabilities total | 128.21 | 153.22 | 317.50 | 456.23 | 372.82 |
| Balance sheet total (liabilities) | 1 058.58 | 1 402.23 | 1 778.83 | 2 631.05 | 2 375.73 |
Secure checkout
Buy AI Credit Risk Report
Pay by card and the report is generated automatically and sent to your email. One-time payment – no subscription.
How it works
- 01 You pay €3 (incl. VAT) securely by card via Stripe.
- 02 You enter your email address in Stripe's payment window – the report is sent there.
- 03 The report is generated automatically and sent as a PDF within 30 minutes.
- 04 If generation should fail, you are not charged.
- 05 You receive the receipt by email once the report has been generated and completed.
Do you want to buy the AI Credit Risk Report (3 EUR / report)?
The report is sent to the email address you enter in Stripe's payment window. Please also check your spam folder. Questions? Write to info@creditreports.dk.
Page generated